Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma. [View article] Wednesday 24 October 2018 10:40 Categories: Media Coverage SCIB1 Year - 2018 Previous Post << >> Next Post